BACKGROUND: Many patients with hypertension have legitimate reasons to forego standard blood pressure targets yet are nonetheless included in performance measurement systems. An approach to performance measurement incorporating clinical reasoning was developed to determine which patients to include in a performance measure. DESIGN: A 10-member multispecialty advisory panel refined a taxonomy of situations in which the balance of benefits and harms of anti-hypertensive treatment does not clearly favor tight blood pressure control (< 140/90 mm Hg). FINDINGS: The panel identified several broad categories of reasons for exempting a patient from performance measurement for blood pressure control. These included (1) patients who have suffered adverse effects from multiple classes of antihypertensive medications; (2) patients already taking four or more antihypertensive medications; (3) patients with terminal disease, moderate to severe dementia, or other conditions that overwhelmingly dominate the patient's clinical status; and (4) other patient factors, including comfort care orientation and poor medication adherence despite attempts to remedy adherence difficulties. Several general principles also emerged. Performance measurement should focus on patients for whom the benefits of treatment clearly outweigh the harms and should incorporate a longitudinal approach. In addition, the criteria for exempting a patient from performance measurement should be more strict in patients at higher risk of adverse health outcomes from hypertension and more lenient for patients at lower risk. CONCLUSIONS: Incorporating "real world" clinical principles and judgment into performance measurement systems may improve targeting of care and, by accounting for patient case mix, allow for better comparison of performance between institutions.
BACKGROUND: Many patients with hypertension have legitimate reasons to forego standard blood pressure targets yet are nonetheless included in performance measurement systems. An approach to performance measurement incorporating clinical reasoning was developed to determine which patients to include in a performance measure. DESIGN: A 10-member multispecialty advisory panel refined a taxonomy of situations in which the balance of benefits and harms of anti-hypertensive treatment does not clearly favor tight blood pressure control (< 140/90 mm Hg). FINDINGS: The panel identified several broad categories of reasons for exempting a patient from performance measurement for blood pressure control. These included (1) patients who have suffered adverse effects from multiple classes of antihypertensive medications; (2) patients already taking four or more antihypertensive medications; (3) patients with terminal disease, moderate to severe dementia, or other conditions that overwhelmingly dominate the patient's clinical status; and (4) other patient factors, including comfort care orientation and poor medication adherence despite attempts to remedy adherence difficulties. Several general principles also emerged. Performance measurement should focus on patients for whom the benefits of treatment clearly outweigh the harms and should incorporate a longitudinal approach. In addition, the criteria for exempting a patient from performance measurement should be more strict in patients at higher risk of adverse health outcomes from hypertension and more lenient for patients at lower risk. CONCLUSIONS: Incorporating "real world" clinical principles and judgment into performance measurement systems may improve targeting of care and, by accounting for patient case mix, allow for better comparison of performance between institutions.
Authors: Monika M Safford; Richard Shewchuk; Haiyan Qu; Jessica H Williams; Carlos A Estrada; Fernando Ovalle; Jeroan J Allison Journal: J Gen Intern Med Date: 2007-10-24 Impact factor: 5.128
Authors: Eve A Kerr; Brian J Zikmund-Fisher; Mandi L Klamerus; Usha Subramanian; Mary M Hogan; Timothy P Hofer Journal: Ann Intern Med Date: 2008-05-20 Impact factor: 25.391
Authors: Nigel S Beckett; Ruth Peters; Astrid E Fletcher; Jan A Staessen; Lisheng Liu; Dan Dumitrascu; Vassil Stoyanovsky; Riitta L Antikainen; Yuri Nikitin; Craig Anderson; Alli Belhani; Françoise Forette; Chakravarthi Rajkumar; Lutgarde Thijs; Winston Banya; Christopher J Bulpitt Journal: N Engl J Med Date: 2008-03-31 Impact factor: 91.245
Authors: Daniel J Oates; Dan R Berlowitz; Mark E Glickman; Rebecca A Silliman; Ann M Borzecki Journal: J Am Geriatr Soc Date: 2007-03 Impact factor: 5.562
Authors: Gail Ardery; Barry L Carter; Jessica L Milchak; George R Bergus; Jeffrey D Dawson; Paul A James; Carrie Franciscus; Yoonsang Kim Journal: J Clin Hypertens (Greenwich) Date: 2007-02 Impact factor: 3.738
Authors: Donna M Zulman; Steven M Asch; Susana B Martins; Eve A Kerr; Brian B Hoffman; Mary K Goldstein Journal: J Gen Intern Med Date: 2013-10-01 Impact factor: 5.128